- Details
- Description
LuciDasa 20 (Dasatinib) is a prescription medicine containing dasatinib, a tyrosine kinase inhibitor (TKI) used in the treatment of certain types of leukemia. Dasatinib works by inhibiting abnormal tyrosine kinase proteins, including BCR-ABL, which are involved in the growth and survival of certain leukemia cells.
LuciDasa 20 is used for appropriate patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) and certain forms of Ph+ acute lymphoblastic leukemia (ALL), according to the prescribing physician's assessment.
Active Ingredient: Dasatinib 20 mg
Dosage Form: Oral tablet
Therapeutic Category: Tyrosine kinase inhibitor
Prescription Status: Prescription medicine
Strength: 20 mg
Route of Administration: Oral
LuciDasa 20 should be taken exactly as prescribed by a healthcare professional. Treatment may require monitoring of blood counts, liver function, and other clinical parameters. Potential adverse effects include low blood-cell counts, fluid retention, diarrhea, headache, nausea, and other reactions.
